Agent for treatment of inflammatory bowel disease

Details Agent for treatment of inflammatory bowel disease Agent for treatment of inflammatory bowel disease

2007-12-25

2007-12-25

Mertz, Prema (Department: 1646)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S885000

Reexamination Certificate

active

10748490

ABSTRACT:
The present invention provides a therapeutic agent for treating inflammatory bowel diseases comprising as an active ingredient at least one member selected from polypeptides belonging a family exhibiting thioredoxin activity.

REFERENCES:
Sido et al (2005), European Journal of Immunology, pp. 408-417.
Claudio Fiocchi, “Inflammatory Bowel Disease: Etiology and Pathogenesis,” Gastroenterology: 115, pp. 182-205 published in 1998.
Tagaya, et al., “ATL-derived factor (ADF), an IL-2 receptor/Tac inducer homologous to thioredoxin; possible involvement of dithiol-reduction in the IL-2 receptor induction,” The EMBO Journal vol. 8, No. 3, pp. 757-764 published in 1989.
Powis, et al., “Properties and Biological Activities of Thioredoxins,” Annual Reviews in Biphysics and Biomolecular Structure: 30 pp. 421-455 published in 2001.
Lih-Brody, et al., “Increased Oxidative Stress and Decreased Antioxidant Defenses in Mucosa of Inflammatory Bowel Disease,” Digestive Diseases and Science, vol. 41, No. 10 pp. 2078-2086 published in 1996.
McKenzie, et al., “Evidence of Oxidant-induced Injury to Epithelial Cells during Inflammatory Bowel Disease,” Journal Clinical Investigation vol. 98, pp. 136-141 published in 1996.
Korenaga, et al., “Impaired Antioxidant Defense System of Colonic Tissue and Cancer Development in Dextran Sulfate Sodium-Induced Colitis in Mice,” Journal of Surgical Research 102, pp. 144-149 published in 2002.
Okayasu, et al., “A Novel Method in the Induction of Reliable Experimental Acute and Chronic Ulcerative Colitis in Mice,” Gastroenterology; 98 pp. 694-702 published in 1990.
Ohkawara, et al., “Amelioration of Dextran Sulfate Sodium-Induced Colitis by Anti-macrophage Migration Inhibitory Factor Antibody in Mice,” Gastroenterology; 123 pp. 256-270 published in 2002.
Jeffers, et al., “A Novel Human Fibroblast Growth Factor Treats Experimental Intestinal Inflammation,” Gastroenterology; 123. pp. 1151-1162 published in 2002.
Williams, et al., “Enhanced Survival and Mucosal Repair After Dextran Sodium Sulfate-Induced Colitis in Transgenic Mice That Overexpress Growth Hormone,” Gastroenterology; 120 pp. 925-937 published in 2001.
Kruidenier, et al., “Review article: oxidative stress as a pathogenic factor in inflammatory bowel disease—radicals or riduculous?” Alimentart Pharmacology & Therpeutics; 16 pp. 1997-2015 published in 2002.
Nakamura, et al., “Circulating thioredoxin suppresses lipopolysaccharide-induced neutrophil chemotaxis,” Proceedings of the National Academy of Science of the United States of America vol. 98, No. 26 pp. 15143-15148 published in Dec. 18, 2001.
Nakamura, et al., “Chronic elevation of plasma thioredoxin: Inhibition of chemotaxis and curtailment of life expectancy in AIDS,” Proceedings of the National Academy of Science of the United States of America vol. 98, No. 5 pp. 2688-2693 published in Feb. 27, 2001.
Powis, et al., “Properties and Biological Activities of Thioredoxins,” Annual Reviews of Pharmacology and Toxicology 41 pp. 216-295 published in 2001.

Affiliated with

Also associated with

Rating

Agent for treatment of inflammatory bowel disease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Agent for treatment of inflammatory bowel disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Agent for treatment of inflammatory bowel disease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3849741